NEVRO CORP's ticker is NVRO and the CUSIP is 64157F103. A total of 195 filers reported holding NEVRO CORP in Q1 2017. The put-call ratio across all filers is 0.77 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2018 | $7,630,000 | -12.5% | 95,560 | -5.0% | 0.32% | -13.2% |
| Q1 2018 | $8,718,000 | +26.0% | 100,590 | +0.3% | 0.37% | +26.6% |
| Q4 2017 | $6,921,000 | -23.5% | 100,250 | +0.7% | 0.29% | -24.1% |
| Q3 2017 | $9,046,000 | +23.4% | 99,540 | +1.1% | 0.39% | +22.2% |
| Q2 2017 | $7,331,000 | -19.5% | 98,490 | +1.4% | 0.32% | -22.7% |
| Q1 2017 | $9,103,000 | – | 97,150 | – | 0.41% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Consonance Capital Management LP | 1,446,333 | $82,441,000 | 4.44% |
| Asymmetry Capital Management, L.P. | 31,379 | $1,789,000 | 1.65% |
| TIRSCHWELL & LOEWY INC | 194,470 | $11,085,000 | 1.38% |
| ZEVENBERGEN CAPITAL INVESTMENTS LLC | 673,480 | $38,388,000 | 1.22% |
| DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) | 525,040 | $29,927,000 | 1.07% |
| Orbimed Advisors | 1,357,691 | $77,388,000 | 0.93% |
| Sio Capital Management, LLC | 45,091 | $2,570,000 | 0.88% |
| PURA VIDA INVESTMENTS, LLC | 60,000 | $3,420,000 | 0.72% |
| SUMMIT PARTNERS PUBLIC ASSET MANAGEMENT, LLC | 159,800 | $9,109,000 | 0.62% |
| Endurant Capital Management LP | 24,171 | $1,378,000 | 0.61% |